The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

ALBUQUERQUE, N.M. (KRQE) – The Lovelace Heart Hospital is celebrating the new addition of their 1,000th heart device. Called ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Due to the risk of atrial fibrillation recurrence following ... In the trial, approximately 60% of device patients had their WATCHMAN FLX implant 90-180 days following their ablation procedure.

Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...